In mouse models, preconditioning tumor-bearing mice with a CDK4/6 inhibitor significantly improved the efficacy of anti-PD-1 ICB therapy.486 Taken together, these results suggest CDK4/6 inhibition in combination with immunotherapy is a promising therapeutic strategy but still needs further investigation. This evidence concerns the gene CDK4 and neoplasm.